Healthcare Robotics Market

On 14 March 2024, the US Food and Drug Administration cleared da Vinci 5, Intuitive’s fifth-generation surgical robot, with force feedback that lets surgeons feel the pressure their instruments put on tissue and about 10,000 times the computing power of the system it replaced. Hospitals that had spent a decade buying the previous model now face a new upgrade cycle, and rival robots from Medtronic, Johnson & Johnson and a wave of Chinese and European makers are chasing the same operating rooms. Douglas Insights values the healthcare robotics market at USD 18.4 billion in 2025 and forecasts USD 65.1 billion by 2035, a compound growth rate of 13.44%. The receipt is an installed base of about 95,000 healthcare robots in service in 2025, from surgical systems to pharmacy, rehabilitation and hospital logistics robots, generating an average of USD 194,000 a year each in system sales, instruments and service. The installed base grows 11.0% a year as robots spread to more hospitals, procedures and countries; revenue per robot grows 2.2% a year as each system is used for more procedures and carries more instruments and software. The report sits within Douglas Insights coverage of medical devices and follows the published Douglas Insights research methodology.

What is the healthcare robotics market?

The healthcare robotics market covers robots that perform or assist medical work, about 95,000 robots in service worth USD 18.4 billion in 2025 revenue. Surgical robotic systems assist surgeons in soft-tissue, orthopaedic, spinal, neurological and endoluminal procedures. Surgical instruments, accessories and service cover the single-use and limited-use instruments, drapes and service contracts each surgical robot consumes. Pharmacy and hospital automation robots dispense medicines, compound intravenous drugs and carry supplies around hospitals. Rehabilitation and assistive robots, including exoskeletons and robotic therapy devices, help patients walk and regain arm movement after strokes and injuries. Disinfection, telepresence and other robots clean rooms with ultraviolet light and let clinicians see patients remotely. The market counts system sales, instruments, accessories, software and service at manufacturer revenue. Laboratory automation, prosthetic limbs and general-purpose industrial robots used in medical factories sit outside the boundary.

How does the da Vinci 5 clearance change healthcare robotics?

The da Vinci 5 clearance starts a replacement cycle across the world’s largest surgical robot fleet, and Douglas Insights estimates it will drive about 5,000 system upgrades and new placements between 2024 and 2030 worth more than USD 10 billion in system sales. Intuitive’s filing on the clearance described a multiport system cleared for most of the procedures the earlier Xi model covers. Force feedback, better imaging and data tools give hospitals a reason to trade up, and each new system brings years of instrument and service revenue. Douglas Insights threads the clearance through this report: it lifts surgical system sales in North America first, it raises the bar for rival robots, and the pace of hospital replacement is one of the swings in the scenarios.

Why are hospitals buying healthcare robots?

Hospitals are buying healthcare robots because they can do more complex procedures through small incisions and do routine work with fewer staff, and Douglas Insights estimates robot-assisted procedures passed 3.5 million worldwide in 2025. Robotic surgery can shorten hospital stays for procedures such as prostate removal, hysterectomy and hernia repair, and surgeons trained on robots increasingly prefer them. Outside the operating room, nursing and pharmacy staff shortages push hospitals to automate drug dispensing and supply delivery. A hospital pharmacy robot can dispense thousands of doses a day with fewer errors, and a delivery robot can save nurses and porters several kilometres of walking per shift.

What drives healthcare robotics demand to 2035?

Four drivers carry healthcare robotics installed-base growth of 11.0% a year, and the spread of robotic surgery to more procedures is the largest. Robots began in urology and gynaecology but now handle general surgery such as hernia, colorectal and gallbladder operations, and orthopaedic robots guide knee, hip and spine surgery. Douglas Insights values surgical instruments, accessories and service at USD 8.48 billion in 2025, 46% of the market, growing 14.6% a year as procedure volumes rise about 15% a year. General surgery is now the largest robotic specialty in the United States, and each new procedure type adds instruments designed for it, such as staplers and energy devices.

Competition and lower-cost systems are the second driver. Medtronic’s Hugo, Johnson & Johnson’s platforms, CMR Surgical’s Versius and Chinese systems from MicroPort and others offer hospitals alternatives, often at lower prices or through leasing, which opens robotics to smaller hospitals and emerging markets. Douglas Insights values surgical robotic systems at USD 4.79 billion in 2025, growing 11.6% a year, and estimates that robots in China, India and Southeast Asia will grow from about 12% of the global surgical fleet in 2025 to about 25% by 2035.

Staff shortages are the third driver. The World Health Organization projects a shortfall of about 11 million health workers by 2030, and pharmacy, nursing and logistics tasks are the easiest to automate. Douglas Insights values pharmacy and hospital automation robots at USD 2.21 billion in 2025, growing 13.0% a year. A large hospital can pay back an IV compounding robot in two to four years through lower waste, fewer errors and less overtime, which is why these robots now sell even in health systems with tight budgets.

Ageing and rehabilitation are the fourth driver. Stroke, spinal injury and age-related mobility loss create demand for robotic therapy and exoskeletons that let one therapist treat more patients. Douglas Insights values rehabilitation and assistive robots at USD 1.66 billion in 2025 and models them growing 15.4% a year, the fastest of any segment, as more insurers pay for robotic therapy. Pressure ulcers in immobile patients, sized in the Wound Care Market report, are one cost that earlier mobility can avoid. Stroke affects about 12 million people a year worldwide, according to the World Stroke Organization, and most survivors need months of rehabilitation that robots can make more intensive.

What could restrain healthcare robotics sales?

Three restraints are built into the healthcare robotics forecast, and cost is the first. A surgical robot costs USD 1 million to USD 2.5 million, plus USD 100,000 to USD 200,000 a year in service and USD 700 to USD 3,500 of instruments per procedure. Douglas Insights estimates many smaller hospitals need 150 to 250 robotic procedures a year to break even, which limits adoption outside large centres.

Evidence and reimbursement are the second restraint. For some procedures, studies show robotic surgery costs more without clearly better outcomes, and most payers do not pay extra for it. Douglas Insights holds revenue per robot growth at 2.2% a year partly because hospitals push back on instrument prices.

Regulation and training are the third restraint. New robots need FDA clearance, CE marking under the EU Medical Device Regulation or NMPA approval in China, and surgeons need structured training. The FDA has warned against using robots for some cancer surgeries without clearance for those uses. Douglas Insights estimates it takes 5 to 8 years for a new surgical robot to move from first clearance to broad adoption.

Which healthcare robotics segments carry the value?

Surgical instruments, accessories and service lead the healthcare robotics market with 46% of 2025 value, while rehabilitation and assistive robots are the fastest-growing segment at 15.4% a year. Every segment holds its share for a different reason.

Surgical instruments, accessories and service are worth USD 8.48 billion in 2025. They lead because every robotic procedure uses instruments with a limited number of lives, so revenue grows with procedure volume rather than system sales.

Surgical robotic systems are worth USD 4.79 billion in 2025. System sales are lumpy and increasingly leased, but each placement locks in years of instrument revenue.

Pharmacy and hospital automation robots are worth USD 2.21 billion in 2025, carried by dispensing cabinets, IV compounding robots and autonomous delivery robots.

Rehabilitation and assistive robots are worth USD 1.66 billion in 2025 and form the fastest-growing segment at 15.4% a year, as stroke and spinal rehabilitation centres adopt robotic therapy and exoskeletons.

Disinfection, telepresence and other robots are worth USD 1.29 billion in 2025. Demand jumped during the pandemic and has since settled, so growth is slowest at 9.0% a year.

How do end users split healthcare robotics demand?

By end user, hospitals account for USD 13.1 billion (71%) of 2025 value, ambulatory surgery centres for USD 2.58 billion (14%), rehabilitation centres and clinics for USD 1.57 billion (8.5%), and home and long-term care for USD 1.20 billion (6.5%). Ambulatory surgery centres are the fastest-growing buyers of surgical robots, as orthopaedic and general surgery moves out of hospitals in the United States.

Why do surgical robots earn most of their money after the sale?

Surgical robots earn most of their money after the sale because each robotic procedure uses instruments and accessories, and Douglas Insights estimates that recurring revenue from instruments, accessories and service made up about 64% of surgical robotics revenue in 2025. A busy multiport robot performing 400 procedures a year generates USD 0.6 million to USD 1.2 million a year in instruments and service, so over a seven-year life it can earn two to four times its purchase price. This model gives makers steady revenue even when hospitals delay capital purchases, and it explains why rivals price systems aggressively or offer them on leases: winning the placement matters more than the system margin. It also explains why hospitals watch utilisation closely, since an idle robot still costs its service fee.

Which regions buy the most healthcare robotics?

North America buys 45.5% of healthcare robotics by value, USD 8.39 billion in 2025, while Asia Pacific grows fastest at 15.4% a year. The United States has the largest installed base of surgical robots, the highest procedure rates and a large ambulatory surgery sector. The region grows 12.6% a year.

Europe buys USD 4.61 billion and grows 12.8% a year, with national health systems buying more robots as waiting lists grow and CMR Surgical and other European makers compete with Intuitive.

Asia Pacific buys USD 4.33 billion and grows 15.4% a year, the fastest rate, as China approves domestic robots and expands quotas for hospital purchases, Japan and Korea add robots for ageing populations, and India’s private hospitals adopt robotic surgery. Latin America buys USD 553 million and grows 13.8%. The Middle East is the wildcard at USD 369 million and 14.6% a year, where Gulf hospital groups buy the latest systems. Africa buys USD 184 million and grows 12.4%.

Who are the leading healthcare robotics companies?

Douglas Insights estimates that the three largest healthcare robotics companies hold about 60% of 2025 value, led by Intuitive at about 52%.

Advantage in healthcare robotics rests on installed base and surgeon training. Intuitive has trained tens of thousands of surgeons and placed more than 10,000 systems, so hospitals face high switching costs; Stryker leads orthopaedics by tying Mako to its own implants; Medtronic and Johnson & Johnson use hospital relationships to sell new systems. In non-surgical robots, Omnicell and Swisslog lead pharmacy automation, and rehabilitation robots come from specialists such as DIH and Ekso Bionics.

How are healthcare robots priced?

Healthcare robots generated an average of USD 194,000 a year each in 2025 revenue, and Douglas Insights expects about USD 241,000 by 2035. A multiport surgical robot costs USD 1.5 million to USD 2.5 million, a single-port or lower-cost system USD 0.7 million to USD 1.5 million, and an orthopaedic robot USD 0.5 million to USD 1.2 million. Surgical instruments cost USD 700 to USD 3,500 per procedure, and service contracts USD 100,000 to USD 200,000 a year. A hospital pharmacy robot costs USD 0.5 million to USD 2 million, an autonomous delivery robot USD 50,000 to USD 150,000, and a rehabilitation exoskeleton USD 75,000 to USD 150,000. Leasing and pay-per-procedure models are spreading, turning capital purchases into operating costs.

Which rules apply to healthcare robotics?

Healthcare robots are medical devices: in the United States most surgical robots are cleared through the FDA’s 510(k) or de novo pathways, in Europe they need CE marking under the Medical Device Regulation, and in China NMPA approval, with Chinese provinces also setting quotas for large medical equipment purchases. Safety standards such as IEC 80601-2-77 for robotically assisted surgical equipment and IEC 60601 for electrical safety apply, and cybersecurity rules now cover connected robots. Surgeon training and credentialing are set by hospitals and professional bodies.

How are data and AI changing healthcare robotics?

Data and AI are turning healthcare robots into sources of procedure data as well as tools, and Douglas Insights estimates that robots recording video, kinematics and outcomes cover most of the more than 3.5 million robotic procedures performed in 2025. Makers use that data to coach surgeons, benchmark performance and design new instruments, and AI tools can flag anatomy or suggest the next step. Hospital logistics robots use AI to navigate corridors and lifts without fixed tracks. This data creates new software revenue and strengthens the lock-in of large installed bases, but it also raises privacy and cybersecurity questions that regulators are only beginning to address.

How far could healthcare robotics reach under each scenario?

The base scenario takes the healthcare robotics market to USD 65.1 billion by 2035, with a range of USD 39.9 billion to USD 93.6 billion. The base case combines 11.0% installed-base growth with 2.2% growth in revenue per robot for 13.44% a year. The slower scenario assumes hospital budgets tighten, payers push back on costs and new robots take longer to clear, setting the legs at 7.5% and 0.5% for USD 39.9 billion. The faster scenario assumes lower-cost robots spread quickly in Asia and ambulatory centres and AI features raise value, setting the legs at 14.0% and 3.2% for USD 93.6 billion. Each 1-point change in installed-base growth moves the 2035 figure by about USD 6.1 billion.

Douglas Exclusive: the robotic procedure and installed base tracker

The robotic procedure and installed base tracker follows, for 30 countries, the installed base of surgical and non-surgical robots by maker and model, robotic procedures by specialty, utilisation per system and regulatory approvals, so suppliers and hospitals can see where adoption is rising. Related markets are covered in the Surgical Robotics Instrument Consumables Market, Hospital Endoscopy Equipment Market and Hospital Sterile Processing Department Equipment Market reports.

Methodology and receipts

The healthcare robotics model is built bottom-up from the installed base. The headline receipt is about 95,000 robots in service multiplied by USD 194,000 of annual revenue per robot, giving USD 18.4 billion for 2025. Installed bases are built for 30 countries from company filings, regulatory approvals and hospital surveys, and revenue per robot from system prices, procedure volumes, instrument use and service contracts, reconciled with reported revenue of listed makers. Surgical robots are counted by system and procedure data from about 20 makers, non-surgical robots by shipment estimates and hospital installation records, and double counting between the two is removed where a maker sells both. The forecast compounds 11.0% installed-base growth and 2.2% revenue-per-robot growth from the 2025 base to about 270,000 robots and USD 65.1 billion in 2035.

Sources

1. U.S. Securities and Exchange Commission (EDGAR) Intuitive announces FDA clearance of fifth-generation robotic system, da Vinci 5 (Form 8-K Exhibit 99.1) (2024)
2. World Health Organization WHO Global Health Observatory: health workforce (2026)
3. United Nations Statistics Division UN Comtrade: trade flows in medical instruments and robots (2026)